Combating the Drug Resistance of Cisplatin Using a Platinum Prodrug Based Delivery System

Abstract

Resistance is futile: A platinum(IV) prodrug conjugated to a gold-nanorod-based delivery agent avoids the type of drug resistance that is associated with cisplatin (see picture). This conjugate is taken up into cells through endocytosis, thus avoiding the resistance-associated uptake mediated by the copper transport protein Ctr1. The platinum(IV) prodrug is more inert than cisplatin to glutathione and metallothionein, which cause deactivation. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.